Purpose. To retrospectively evaluate the effectiveness of intra-articular application of Sluijter-Teixera Poisson pulsed radiofrequency (STP PRF) in knee osteoarthritis symptomatic patients with chronic pain refractory to conservative therapies. Materials and Methods. Institutional database research of two centers identified 39 cases of knee osteoarthritis patients treated with intra-articular STP PRF. Pain prior and one-week and one-, three-, six-, and twelve-month post-STP PRF was compared by means of a numeric visual scale (NVS) questionnaire. Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification system was used for complications reporting. Mean patient age was 71.59 ± 11.99 years, mean body mass index was 30.23 ± 4.69, and male/female ratio was 9/30. Results. Mean baseline pain score was 8.31 ± 1.70 NVS units. This was reduced to a mean value of 0.90 ± 1.50 NVS units one-week post-RF, 1.08 ± 1.53 at one month, 1.54 ± 1.88 at three months, 2.33 ± 2.17 at six months, and 3.23 ± 2.23 at 12 months of follow-up . Pain decrease of more than 4 NVS units was noticed in 35/39 knees (89.7%) at first week, 36/39 knees (92.3%) at first month, 35/39 knees (89.7%) at three months, 32/39 knees (82.1%) at six months, and 25/39 knees (64.1%) at one year. There was no recurrence during the follow-up. No complication was observed. Conclusions. Percutaneous, intra-articular application of STP PRF is an effective and safe technique for chronic pain reduction in patients with knee osteoarthritis. Results seem to be reproducible and long lasting with significant patient satisfaction at 12-month follow-up.

中文翻译：

---

Sluijter-Teixera泊松脉冲射频在有症状的膝骨关节炎患者中的关节内应用：关注临床疗效和安全性

目的。回顾性评估关节内应用 Sluijter-Teixera Poisson 脉冲射频 (STP PRF) 对保守治疗无效的慢性疼痛的膝骨关节炎症状患者的有效性。材料和方法。两个中心的机构数据库研究确定了 39 例接受关节内 STP PRF 治疗的膝骨关节炎患者。通过数字视觉量表 (NVS) 问卷对 STP PRF 之前和 1 周以及 1、3、6 和 12 个月后的疼痛进行了比较。欧洲心血管和介入放射学会 (CIRSE) 分类系统用于并发症报告。平均患者年龄为 71.59 ± 11.99 岁，平均体重指数为 30.23 ± 4.69，男女比例为 9/30。结果。平均基线疼痛评分为 8.31 ± 1.70 NVS 单位。RF 后一周的平均值减少为 0.90 ± 1.50 NVS 单位，一个月时为 1.08 ± 1.53，三个月时为 1.54 ± 1.88，六个月时为 2.33 ± 2.17，并且在后续的 12 个月时为 3.23 ± 2.23 -向上. 第一周有 35/39 膝（89.7%）、第一个月有 36/39 膝（92.3%）、三个月有 35/39 膝（89.7%）、32/39 发现疼痛减少超过 4 个 NVS 单位6 个月时膝盖 (82.1%)，一年时 25/39 膝盖 (64.1%)。随访期间无复发。没有观察到并发症。结论。经皮、关节内应用 STP PRF 是一种有效且安全的技术，可减轻膝关节骨关节炎患者的慢性疼痛。结果似乎具有可重复性和持久性，在 12 个月的随访中患者满意度显着。